

**Harm Reduction Coalition
Health Bulletin Volume 1
January 2009
Working With Active Drug Users
References/Sources**

1. Frank B. An overview of heroin trends in New York City: Past, present, and future. *Mt Sinai J Med.* 2000 Oct-Nov; 67(5-6):340-6.
2. Friedman SR, Lieb S, Tempalski B, Cooper H, Keem M, Friedman R, Flob PL. HIV among injection drug users in large US metropolitan areas, 1998. *J Urban Health.* 2005 Sep;82(3):434-45
3. Coffin PO, Galea S, Ahern J, Leon AC, Vlahov D, Tardiff K. Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990-98. *Addiction.* 2003 Jun; 98(6):739-47.
4. Miller NS, Sheppard LM, Colenda CC, Magen J. Why physicians are unprepared to treat patients who have alcohol- and drug-related disorders. *Acad Med.* 2001 May; 76(5):410-8.
5. Elovich R, Wolfe D. Substance Users in Ruth Finkelstein, ScD and Sandra E. Ramos, PhD eds *Manual for Primary Care Providers: Effectively Caring for Active Substance Users*, New York Academy of Medicine, 2002
6. Schrag D, Xu F, Hanger M, Elkin E, Bickell NA, Back PB. Fragmentation of care for frequently hospitalized urban residents. *Med Care.* 2006 Jun; 44(6):560-7.
7. Ahern J, Stuber J, Galea S. Stigma, discrimination and the health of illicit drug users. *Drug Alcohol Depend.* 2007 May 11; 88(2-3):188-96.
8. Simmonds L, Coomber R. Injecting drug users: A stigmatised and stigmatising population. *Int J Drug Policy.* 2007 Nov 2
9. Des Jarlais, D.C., Perlis, T., Friedman, S.F., Chapman, T., Kwok, J., Rockwell, R., Paone, D., Milliken, J., Monterroso, E. (2000). Behavioral Risk Reduction in a Declining HIV Epidemic: Injection Drug Users in New York City, 1990-1997. *American Journal of Public Health*, 90(7), 1112-1116.
10. Perlman DC, Perkins MP, Solomon N, Kochems L, Des Jarlais DC, Paone D. Tuberculosis screening at a syringe exchange program. *Am J Public Health.* 1997 May; 87(5):862-3
11. Don C. Des Jarlais, PhD, Dennis G. Fisher, PhD, Jessica Clark Newman, MPH, Beth N. Trubatch, BA, Molly Yancovitz, BA, Denise Paone, EdD and David Perlman, MD. (2001). Providing Hepatitis B Vaccination to Injection Drug Users: Referral to Health Clinics vs On-Site Vaccination at a Syringe Exchange

12. Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. *Lancet*. 2007 Mar 24; 369(9566):1047-53.
13. New York State Department of Health
http://www.health.state.ny.us/diseases/aids/harm_reduction
14. Des Jarlais DC, Perlis T, ARasteh K, Torian LV, Hagan H, Beatrice S, Smith L, Wethers J, Milliken J, Mildvan D, Yancovitz S, Frideman SR. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. *AIDS*. 2005 Oct; 19 Suppl 3:S20-5.
15. Arnsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, Howard AA, Schoenbaum EE. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. *J Gen Intern Med*. 2002 May;17(5):377-81
16. Vlahov D, Celentano DD. Access to highly active antiretroviral therapy for injection drug users: adherence, resistance, and death. *Cad Saude Publica*. 2006 Apr; 22(4):705-18.
17. Moore RD, Keruly JC, Chaisson RE. Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. *J Acquir Immune Defic Syndr*. 2004 Jan 1; 35(1):46-51.
18. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. *J Acquir Immune Defic Syndr* 2001; 27:251-9.
19. Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. *J Subst Abuse Treat*. 2005 Oct; 29(3):159-65.
20. Beach MC, Keruly J, Moore RD. Is the quality of the patient-provider relationship associated with better adherence and health outcomes for patients with HIV? *J Gen Intern Med*. 2006 Jun;21(6):661-5
21. Interventions to Prevent HIV Risk Behaviors. NIH Consensus Statement Online 1997 Feb 11-13 Accessed 1/7/07 15(2): 1-41.
22. Stancliff S, Agins B, Rich JD, Burris S. Syringe access for the prevention of blood borne infections among injection drug users. *BMC Public Health*. 2003 Nov 21; 3:37.
23. Rich JD, Macalino GE, McKenzie M, Taylor LE, Burris S. Syringe prescription to prevent HIV infection in Rhode Island: a case study. *Am J Public Health*. 2001 May; 91(5):699-700.

24. Birkhead GS, Klein SJ, Candelas AR, O'Connell DA, Rothman JR, Feldman IS, Tsui DS, Cotroneo RA, Flanigan CA. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach. *Int J Drug Policy*. 2007 Oct; 18(5):417-25.
25. Fuller CM, Galea S, Caceres W, Blaney S, Sisco S, Vlahov D. Multilevel community-based intervention to increase access to sterile syringes among injection drug users through pharmacy sales in New York City. *Am J Public Health*. 2007 Jan; 97(1):117-24.
26. Groseclose SL, Weinstein B, Jones TS, Valleroy LA, Fehrs LJ, Kassler WJ. Impact of increased legal access to needles and syringes on practices of injecting-drug users and police officers--Connecticut, 1992-1993. *J Acquir Immune Defic Syndr Hum Retrovirol*. 1995 Sep 1; 10(1):82-9.
27. Centers for Disease Control and Prevention (CDC). Syringe exchange programs—United States, 2005. *MMWR Morb Mortal Wkly Rep*. 2007 Nov 9; 56(44):1164-7. (MMWR).
28. New York State Department of Health Working with the Active User, HIV and Substance Use, <http://hivguidelines.org/GuideLine.aspx?pageID=262&guideLineID=78>
29. Sporer KA, Kral AH. Prescription naloxone: a novel approach to heroin overdose prevention. *Ann Emerg Med*. 2007.
30. Coffin PO, Tracy M, Bucciarelli A, Ompad D, Vlahov D, Galea S. Identifying injection drug users at risk of nonfatal overdose. *Acad Emerg Med*. 2007 Jul; 14(7):616-23.
31. Chamberlain J M, Klein B L. A Comprehensive Review of Naloxone for the Emergency Physician. *Am J Emerg Med* 1994; **12**: 650–9.
32. van Dorp EL, Yassen A, Dahan A. Naloxone treatment in opioid addiction: the risks and benefits. *Expert Opin Drug Saf*. 2007 Mar; 6(2):125-32.
33. Maxwell 2006 Maxwell S, Bigg D, Stanczykiewicz K, Carlberg-Racich S. Prescribing naloxone to actively injecting heroin users: a program to reduce heroin overdose deaths. *J Addict Dis*. 2006; 25(3):89-96.
34. De Castro S, Sabate E. Adherence to heroin dependence therapies and human immunodeficiency virus/acquired immunodeficiency syndrome infection rates among drug abusers. *Clin Infect Dis*. 2003 Dec 15; 37 Suppl 5:S464-7

35. Caplehorn JR, Dalton MS, Haldar F, Petrenas AM, Nisbet JG. Methadone maintenance and addicts' risk of fatal heroin overdose. *Subst Use Misuse*. 1996 Jan; 31(2):177-96.
36. Fatseas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. *Curr Psychiatry Rep*. 2007 Oct; 9(5):358-64.
37. Edlin, BR Hepatitis C prevention and treatment for substance users in the United States: acknowledging the elephant in the living room *Int J Drug Policy*. 2004 April; 15(2): 81-91.